Se Hoon Park

Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial.

M. Harrison, E. Heath, A. Balar, 2021, The Lancet. Oncology.

Efficacy and safety of morning versus evening dose of controlled-release simvastatin tablets in patients with hyperlipidemia: a randomized, double-blind, multicenter phase III trial.

Sang-Hyun Kim, K. Han, Seong-Wook Cho, 2013, Clinical therapeutics.

Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study.

T. Powles, T. Choueiri, B. Melichar, 2023, The Lancet. Oncology.